Impact of vaccination on post-acute sequelae of SARS CoV-2 infection in patients with rheumatic diseases

Naomi J. Patel, Claire Cook, Kathleen M.m. Vanni, Xiaoqing Fu, Xiaosong Wang, Yumeko Kawano, Grace Qian, Buuthien Hang, Shruthi Srivatsan, Emily Banasiak, Emily Kowalski, Katarina J Bade, Yuqing Zhang, Jeffrey A. Sparks, Zachary S. WallacemedRxiv 2022 · DOI

Abstract

Vaccination is known to reduce the risk of severe COVID-19, but its effect on post-acute sequelae of COVID-19 (PASC) among patients with systemic autoimmune rheumatic diseases (SARDs) has remained unclear. This study prospectively evaluated 280 SARD patients to determine the impact of vaccination on PASC risk. Results indicate that patients with breakthrough infections experienced significantly more symptom-free days and a substantially lower risk of PASC at 90 days (aOR 0.10) compared to those with non-breakthrough infections. These findings underscore the critical role of vaccination in protecting this vulnerable population from long-term COVID-19 complications.

Introduction

Post-acute sequelae of SARS-CoV-2 (PASC), commonly known as "Long COVID," is a debilitating condition affecting 20–50% of COVID-19 survivors. For individuals with systemic autoimmune rheumatic diseases (SARDs)—such as rheumatoid arthritis or systemic lupus erythematosus—the stakes are particularly high. These patients often utilize immunosuppressive therapies that can dampen vaccine immunogenicity, potentially leaving them more susceptible to both acute severity and the lingering symptoms of PASC. While vaccination has proven effective in the general population, its efficacy in preventing PASC within the SARD community required dedicated investigation.

Methodology

The researchers utilized the RheumCARD cohort, a prospective study within the Mass General Brigham healthcare system. The study followed 280 adult SARD patients who survived an acute COVID-19 infection. Participants were categorized into two groups:

  1. Breakthrough Infection: Patients who were fully vaccinated at least 14 days prior to their diagnosis (n=116).
  2. Non-breakthrough Infection: Patients who were unvaccinated or only partially vaccinated at the time of infection (n=164).

The primary outcomes were the odds of PASC at 28 days (CDC definition) and 90 days (WHO definition), analyzed using multivariable logistic regression. Additionally, Restricted Mean Survival Time (RMST) was employed to compare the "symptom-free duration" over a 204-day follow-up period, adjusting for age, sex, race, comorbidities, and specific medications like methotrexate or anti-CD20 antibodies.

Results

The study revealed a stark contrast between the two groups regarding long-term recovery and symptom duration.

Risk Reduction

Vaccination was associated with a significant decrease in the likelihood of developing PASC. At the 28-day mark, the adjusted odds ratio (aOR) was 0.49 (95% CI: 0.29, 0.83). By 90 days, the protection was even more pronounced, with an aOR of 0.10 (95% CI: 0.04, 0.22), representing a 90% reduction in risk for the vaccinated group compared to those with non-breakthrough infections.

Symptom-Free Duration

Over the 204-day follow-up period, patients with breakthrough infections enjoyed an average of 28.9 more symptom-free days (95% CI: 8.83, 48.89; p=0.005) than those in the non-breakthrough group. Furthermore, acute severity was significantly lower in the vaccinated group; only 5% of breakthrough cases required hospitalization, compared to 27% of non-breakthrough cases.

Symptom Profiles

The nature of the acute infection also differed by vaccination status. Breakthrough cases primarily reported upper respiratory symptoms, such as sore throat and congestion. In contrast, non-breakthrough cases were more likely to experience systemic and neurological symptoms, including anosmia (loss of smell), dysgeusia (loss of taste), and joint pain.

Discussion

The findings support the "Initial Response" hypothesis, suggesting that the quality of the body's early immune response to SARS-CoV-2 is a primary determinant of PASC development. Even if a patient's immune response to the vaccine is partially blunted by SARD-related medications, the "priming" provided by vaccination likely facilitates faster viral clearance or prevents the hyper-inflammatory state often associated with long-term symptoms.

Interestingly, the study found that while vaccination is highly effective at preventing the transition to PASC, the severity of symptoms among those who did develop PASC was relatively similar across both groups. This suggests the vaccine's primary benefit in this context is prevention rather than symptom mitigation once PASC has already taken hold.

Limitations

Several limitations should be considered. The study period spanned different viral variants; most breakthrough infections occurred during the Omicron wave, while many non-breakthrough infections occurred earlier in the pandemic. Additionally, the reliance on patient-reported surveys introduces the possibility of recall bias. Finally, the cohort was 82% white and treated at a single academic healthcare system, which may limit generalizability to more diverse populations.

Conclusion

This study provides robust evidence that COVID-19 vaccination significantly reduces the risk of PASC in patients with SARDs. Despite potential blunting of vaccine effectiveness due to immunosuppression, the protective benefits against long-term sequelae remain substantial. These results reinforce the importance of vaccination and boosters for patients with autoimmune conditions to mitigate the long-term burden of the pandemic.

Summary updated

Abstract

Abstract Objective Vaccination decreases the risk of severe COVID-19 but its impact on post-acute sequelae of COVID-19 (PASC) is unclear among patients with systemic autoimmune rheumatic diseases (SARDs) who may have blunted vaccine immunogenicity and be vulnerable to PASC. Methods We prospectively enrolled SARD patients from a large healthcare system who survived acute infection to complete surveys. The symptom-free duration and the odds of PASC (any symptom lasting ≥ 28 or 90 days) were evaluated using restricted mean survival time and multivariable logistic regression, respectively, among those with and without breakthrough infection (≥ 14 days after initial vaccine series). Results Among 280 patients, the mean age was 53 years, 80% were female, and 82% were white. The most common SARDs were inflammatory arthritis (59%) and connective tissue disease (24%). Those with breakthrough infection had more upper respiratory symptoms, and those with non-breakthrough infection had more anosmia, dysgeusia, and joint pain. Compared to those with non-breakthrough COVID-19 infection (n=164), those with breakthrough infection (n=116) had significantly more symptom-free days over the follow-up period (+28.9 days, 95% CI: 8.83, 48.89; p=0.005) and lower odds of PASC at 28 and 90 days (aOR 0.49, 95% CI: 0.29, 0.83 and aOR 0.10, 95% CI: 0.04, 0.22, respectively). Conclusion Vaccinated patients with SARDs were less likely to experience PASC compared to those not fully vaccinated. These findings support the benefits of vaccination for patients with SARDs and suggest that the immune response to acute infection is important in the pathogenesis of PASC in SARD patients. Key Messages What is already known on this topic? Post-acute sequelae of COVID-19 (PASC) affects 20-50% of COVID-19 survivors, though the impact of vaccination on the risk and severity of PASC is unclear, especially among those with systemic autoimmune rheumatic diseases (SARDs) who may have impaired responses to vaccines and be particularly vulnerable to PASC. What this study adds? In this prospective cohort of SARD patients recovering from COVID-19, we found that those with breakthrough vs non-breakthrough infection had more symptom-free days over the follow-up period (adjusted difference +28.9 days, 95% CI: 8.38, 48.89; p=0.005) and a lower odds of PASC at 28 days (aOR 0.49, 95% CI: 0.29, 0.83) and at 90 days (aOR 0.10, 95% CI: 0.04, 0.22). Patient-reported pain and fatigue scores were lower, reflecting less severe pain and fatigue, in those with breakthrough infection compared to those with non-breakthrough infection. How this study might affect research, practice, or policy? This study extends our understanding of the benefits of vaccination against COVID-19 in patients living with SARDs and reinforces the importance of vaccinating this vulnerable population. Our findings suggest that the initial immune response to acute SARS-CoV-2, as influenced by vaccination, affects PASC risk but this requires further study.
BibTeX
@misc{patel2022impact,
  author = {Naomi J. Patel and Claire Cook and Kathleen M.M. Vanni and Xiaoqing Fu and Xiaosong Wang and Yumeko Kawano and Grace Qian and Buuthien Hang and Shruthi Srivatsan and Emily Banasiak and Emily Kowalski and Katarina J Bade and Yuqing Zhang and Jeffrey A. Sparks and Zachary S. Wallace},
  title = {{Impact of vaccination on post-acute sequelae of SARS CoV-2 infection in patients with rheumatic diseases}},
  year = {2022},
  doi = {10.1101/2022.10.06.22280798},
  howpublished = {medRxiv},
}
Figure